Publications by authors named "Jaime Rubin"

Claim this Profile
I
Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.
Akshay Sharma, Franco Locatelli, Monica Bhatia, Lyndsay Molinari, Markus Y Mapara, Jaime Rubin

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel.
Josu de la Fuente, Haydar Frangoul, Peter Lang, Donna Wall, Roland Meisel, Jaime Rubin

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.
Jaime L Rubin, Craig McKinnon, Gabriel Ghizzi Pedra, Devon A Morgan, Kimberly Zweig

Pulm Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis.
Christian Merlo, Teja Thorat, Lisa J McGarry, Christina V Scirica, Maral DerSarkissian, Jaime L Rubin

Pulm Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.
Christian A Merlo, Lisa J McGarry, Teja Thorat, Catherine Nguyen, Maral DerSarkissian, Jaime L Rubin

Thorax· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.
Christian A Merlo, Teja Thorat, Maral DerSarkissian, Lisa J McGarry, Catherine Nguyen, Jaime L Rubin

Thorax· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility.
Jaime L Rubin, James L Kreindler

J Cyst Fibros· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
Andrea Lopez, Conor Daly, Gabriela Vega-Hernandez, Gordon MacGregor, Jaime L Rubin

J Cyst Fibros· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
Lisa J McGarry, Zahra Bhaiwala, Andrea Lopez, Conor Chandler, Christopher G Pelligra, Jaime L Rubin

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis.
Jaime L Rubin, Andrea Lopez, Jason Booth, Penilla Gunther, Anupam B Jena

J Med Econ· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs among children with cystic fibrosis in the United States.
Teja Thorat, Lisa J McGarry, Machaon M Bonafede, Brendan L Limone, Jaime L Rubin

Pediatr Pulmonol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Jaime L Rubin

Lancet Respir Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Jaime L Rubin, Lasair O'Callaghan, Christopher Pelligra, Michael W Konstan, Alexandra Ward

Ther Adv Respir Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV.
Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, J Stuart Elborn, Michael P Boyle, Jaime L Rubin

J Cyst Fibros· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.
Jaime L Rubin, Sarah Thayer, Angela Watkins, Jeffrey S Wagener, Paul S Hodgkins

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Michael W Konstan, Edward F McKone, Richard B Moss, Gautham Marigowda, Simon Tian, Jaime Rubin

Lancet Respir Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
Anita J Brogan, Sandra E Talbird, James R Thompson, Jeffrey D Miller, Jaime Rubin

PLoS One· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
M Michele Manos, Jeanne Darbinian, Jaime Rubin, G Thomas Ray, Valentina Shvachko

J Manag Care Pharm· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.
Richard Mutell, Jaime L Rubin, T Christopher Bond, Tracy Mayne

Int J Nephrol Renovasc Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.
Lisa J McGarry, Kristen E Gilmore, Jaime L Rubin, Keith P Klugman, David R Strutton

BMC Infect Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population.
Holly Yu, Jaime Rubin, Stephan Dunning, Suying Li, Reiko Sato

J Am Geriatr Soc· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
David R Strutton, Raymond A Farkouh, Jaime L Rubin, Lisa J McGarry, Paul M Loiacono

BMC Infect Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic model of a birth cohort screening program for hepatitis C virus.
Lisa J McGarry, Vivek S Pawar, Hemangi R Panchmatia, Jaime L Rubin, Gary L Davis

Hepatology· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost estimation of cardiovascular disease events in the US.
Amy K O'Sullivan, Jaime Rubin, Joshua Nyambose, Andreas Kuznik, David J Cohen

Pharmacoeconomics· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, survival, and costs of localized gastrointestinal stromal tumors.
Jaime L Rubin, Myrlene Sanon, Douglas Ca Taylor, John Coombs, Vamsi Bollu

Int J Gen Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis